Evidence map›Paper›PMID 27718369›Full record

Trial reportJournal of psychiatric research2017

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.

Minkyung Park, Laura E Newman, Philip W Gold, David A Luckenbaugh, Peixiong Yuan, Rodrigo Machado-Vieira, Carlos A Zarate

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychiatric research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Minkyung ParkExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA.
Laura E NewmanExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA.
Philip W GoldExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA.
David A LuckenbaughExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA.
Peixiong YuanExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA.
Rodrigo Machado-VieiraExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA. Electronic address: machadovieirar@mail.nih.gov.
Carlos A ZarateExperimental Therapeutics & Pathophysiology Branch, National Institute of Mental Health, NIH, 10 Center Drive, Room 7-5432, Bethesda, MD 20892, USA.
National Institute of Mental Health · US

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Intramural NIH HHS Z99 MH999999
6 · The paper itself

Abstract

Several pro-inflammatory cytokines have been implicated in depression and in antidepressant response. This exploratory analysis assessed: 1) the extent to which baseline cytokine levels predicted positive antidepressant response to ketamine; 2) whether ketamine responders experienced acute changes in cytokine levels not observed in non-responders; and 3) whether ketamine lowered levels of pro-inflammatory cytokines, analogous to the impact of other antidepressants. Data from double-blind, placebo-controlled studies of patients with major depressive disorder (MDD) or bipolar disorder (BD) who received a single infusion of sub-anesthetic dose ketamine were used (N = 80). Plasma levels of the eight cytokines were measured at baseline and at 230 min, 1 day, and 3 days post-ketamine. A significant positive correlation was observed between sTNFR1 and severity of depression at baseline. Cytokine changes did not correlate with changes in mood nor predict mood changes associated with ketamine administration. Ketamine significantly increased IL-6 levels and significantly decreased sTNFR1 levels. IL-6 and TNF-α levels were also significantly higher-and sTNFR1 levels were significantly lower-in BD compared to MDD subjects. The functional significance of this difference is unknown. Changes in cytokine levels post-ketamine were not related to antidepressant response, suggesting they are not a primary mechanism involved in ketamine's acute antidepressant effects. Taken together, the results suggest that further study of cytokine levels is warranted to assess their potential role as a surrogate outcome in the rapid antidepressant response paradigm.

Indexed as

AdultAntidepressive AgentsBiomarkersBipolar DisorderCytokinesDepressive Disorder, Treatment-ResistantDouble-Blind MethodFemaleHumansKetamineLinear ModelsMajor Depressive DisorderMaleMiddle AgedPrognosisTreatment OutcomeAntidepressive AgentsBiomarkersCytokinesKetamineBipolar disorderCytokineInterleukin-6 (IL-6)KetamineMajor depressive disorderSoluble tumor necrosis factor receptor 1 (sTNFR1)

Identifiers

PMID27718369
PMCPMC5125870
OpenAlexW2529017560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.